The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Open accessAbstract
Although the MYC oncogene has been implicated in cancer, a systematic assessment of alterations of MYC, related transcription factors, and co-regulatory proteins, forming the proximal MYC network (PMN), across human cancers is lacking. Using computational approaches, we define genomic and proteomic features associated with MYC and the PMN across the 33 cancers of The Cancer Genome Atlas. Pan-cancer, 28% of all samples had at least one of the MYC paralogs amplified. In contrast, the MYC antagonists MGA and MNT were the most frequently mutated or deleted members, proposing a role as tumor suppressors. MYC alterations were mutually exclusive with PIK3CA, PTEN, APC, or BRAF alterations, suggesting that MYC is a distinct oncogenic driver. Expression analysis revealed MYC-associated pathways in tumor subtypes, such as immune response and growth factor signaling; chromatin, translation, and DNA replication/repair were conserved pan-cancer. This analysis reveals insights into MYC biology and is a reference for biomarkers and therapeutics for cancers with alterations of MYC or the PMN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Myc oncogene, including its three subtypes C-Myc, N-Myc, and L-Myc, is believed to act as a transcriptional “amplifier” that can trigger a variety of oncogenic transcriptional programs in different types of cancer.410,411”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [411]
In the citing paper
“Overexpression or hyperactivation of Myc is one of the most common occurrences in cancer, making it a key factor in oncogenesis.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [411]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Distribution Theory for Glass's Estimator of Effect Size and Related Estimators
Hedges, L. V. (1981) · Journal of Educational Statistics · doi:10.2307/1164588 · Cited by 5,695
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · cited 2×
“More recently, a report broadly analyzing the landscape of focal amplifications in cancers found MYC amplification to be among the most frequent of all such events (Beroukhim et al., 2010).”
Self-citationGregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew‐Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,852 · cited 1×
“…to modulate epithelial-mesenchymal transition (EMT) by forming a negative feedback loop with the master transcription factors ZEB1 and ZEB2 (Burk et al., 2008; Gregory et al., 2008; Korpal et al., 2008; Park (B) The table lists the top four genes most mutually exclusive with respect to MYC .”
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
A microRNA polycistron as a potential human oncogene
He, L., Thomson, J. M., Hemann, M. T., Hernando, E., Mu, D., Goodson, S. G., Powers, S., Cordon‐Cardo, C., Lowe, S. W., Hannon, G. J., et al. (2005) · Nature · doi:10.1038/nature03552 · Cited by 3,642 · cited 2×
“Studies in mouse models of human cancers have demonstrated that this cluster, also known as Oncomir1, is a bona fide oncogene and a direct MYC transcriptional target (He et al., 2005; O’Donnell et al., 2005).”
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,520
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 434
Emerging Themes in Mechanisms of Tumorigenesis by SWI/SNF Subunit Mutation
Jones, C. A., Tansey, W. P., & Weissmiller, A. M. (2022) · Epigenetics Insights · doi:10.1177/25168657221115656 · Cited by 39
Self-citationZhang, Y., Wang, Y., Li, Y., Huang, C., Xiao, X., Zhong, Z., Tang, J., Lu, H., Tang, Y., & Yang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114941 · Cited by 35
Self-citationCurrent and future therapies for small cell lung carcinoma
Zhai, X., Zhang, Z., Chen, Y., Wu, Y., Zhen, C., Liu, Y., Lin, Y., & Chen, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01690-6 · Cited by 35
“) is a major regulator of several biological programs; it exerts most of its functions as a transcription factor, regulating the expression of thousands of genes directly or indirectly, and is one of the most frequently activated products in human cancers [51].”
Self-citationMadonna, M. C., Duer, J. E., Lee, J. V., Williams, J. R., Avşaroğlu, B., Zhu, C., Deutsch, R. J., Wang, R., Crouch, B. T., Hirschey, M. D., et al. (2021) · Cancers · doi:10.3390/cancers13010148 · Cited by 36
Self-citationTranscriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 38
Self-citationLiver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc
Bakiri, L., Hasenfuss, S. C., Guío-Carrión, A., Thomsen, M. K., Hasselblatt, P., & Wagner, E. F. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404188121 · Cited by 34
“The c - Jun ~ Fra - 2 hep GEMM constitutes a convenient model to dissect the interactions between preneoplastic or fully transformed hepatocytes and their nonparenchymal environment. c - Myc and Myc pathway activation is a major oncogenic event in many tumor types including HCC (54, 55).”
BackgroundYang, L., Zhang, Z., Jiang, P., Kong, D., Yu, Z., Shi, D., Han, Y., Chen, E., Zheng, W., Sun, J., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01420-z · Cited by 37
“MYC 50,51 is translationally downregulated by FBL without a change in mRNA level (Fig.”
Self-citationKobliakov, V. A. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919100018 · Cited by 34
Targeting Protein Synthesis in Colorectal Cancer
Schmidt, S., Denk, S., & Wiegering, A. (2020) · Cancers · doi:10.3390/cancers12051298 · Cited by 36
Myc linked to dysregulation of cholesterol transport and storage in nonsmall cell lung cancer
Hall, Z., Wilson, C. H., Burkhart, D. L., Ashmore, T., Evan, G. I., & Griffin, J. L. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000899 · Cited by 35
“overexpressed, focal amplifications occurring in more than 30% of lung adenocarcinomas (3).”
BackgroundTargeting MYC: From understanding its biology to drug discovery
Ross, J., Miron, C. E., Plescia, J., LaPlante, P., McBride, K. M., Moitessier, N., & Möröy, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113137 · Cited by 35
A druggable conformational switch in the c-MYC transactivation domain
Lama, D., Vosselman, T., Sahin, C., Liaño-Pons, J., Cerrato, C. P., Nilsson, L., Teilum, K., Lane, D. P., Landreh, M., & Arsenian‐Henriksson, M. (2024) · Nature Communications · doi:10.1038/s41467-024-45826-7 · Cited by 35
Multi-omics and pharmacological characterization of patient-derived glioma cell lines
Wu, M., Wang, T., Ji, N., Lu, T., Yuan, R., Wu, L., Zhang, J., Li, M., Cao, P., Zhao, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51214-y · Cited by 34
Self-citationDhanasekaran, R., Park, J., Yevtodiyenko, A., Bellovin, D. I., Adam, S. J., Rajan, A., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.008 · Cited by 32
Self-citationThe clear cell sarcoma functional genomic landscape
Panza, E., Ozenberger, B. B., Straessler, K. M., Barrott, J. J., Li, L., Wang, Y., Xie, M., Boulet, A. M., Titen, S. W. A., Mason, C. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146301 · Cited by 30
“Furthermore, while amplified Myc expression and stability were clearly capable of enhancing tumorigenesis when added to EWSR1-ATF1 expression, they did not faithfully maintain the tumor phenotype of CCS, suggesting that, although MYC is — not surprisingly — oncogenic, it may not specifically be a driver of clear cell…”
BackgroundSelf-citationNormal and Neoplastic Growth Suppression by the Extended Myc Network
Wang, H., & Prochownik, E. (2022) · Cells · doi:10.3390/cells11040747 · Cited by 31
“This may partly reflect their high incidence of BRAF, PIK3CA and PTEN mutations, which likely circumvent Myc Network activation [93,99].”
BackgroundInfluentialGadd, S., Huff, V., Skol, A. D., Renfro, L. A., Fernandez, C. V., Mullen, E. A., Jones, C. D., Hoadley, K. A., Yap, K. L., Ramirez, N. C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100644 · Cited by 35
Self-citationCurti, L., Rohban, S., Bianchi, N., Croci, O., Andronache, A., Barozzi, S., Mattioli, M., Ricci, F., Pastori, E., Sberna, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51229-5 · Cited by 33
“The c-MYC proto-oncogene isfrequently overexpressed incancer cells, due to genomic alterations (e.g., translocation, ampli fi cation) or oncogenicmutations in upstream regulatory pathways 10,11 .”
BackgroundMYC Ran Up the Clock: The Complex Interplay between MYC and the Molecular Circadian Clock in Cancer
Burchett, J. B., Knudsen-Clark, A. M., & Altman, B. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147761 · Cited by 32
“in specific cancers; for instance, in ovarian cancer, one of the three MYC paralogues is amplified in nearly 100% of cases [4].”
BackgroundPan-Cancer Analysis Identified C1ORF112 as a Potential Biomarker for Multiple Tumor Types
Chen, J., Mai, H., Chen, H., Zhou, B., Hou, J., & Jiang, D. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.693651 · Cited by 28
“Keywords: C1ORF112, prognosis, pan-cancer, biomarker, cell cycle INTRODUCTION Cancer is the most common cause of death in the world (Sung et al., 2021).”
BackgroundNatural Compounds Targeting Major Signaling Pathways in Lung Cancer
Kumar, S., Sharma, A. K., Lalhlenmawia, H., & Kumar, D. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_37 · Cited by 29
MYC-Targeting Inhibitors Generated from a Stereodiversified Bicyclic Peptide Library
Li, Z., Huang, Y., Hung, T. I., Sun, J., Aispuro, D., Chen, B., Guevara, N., Ji, F., Xu, C., Zhu, L., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09615 · Cited by 28
Mitochondrial sirtuins: Energy dynamics and cancer metabolism
Lee, H., & Yoon, H. (2024) · Molecules and Cells · doi:10.1016/j.mocell.2024.100029 · Cited by 28
More Than Meets the Eye Regarding Cancer Metabolism
Kubicka, A., Matczak, K., & Łabieniec-Watała, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179507 · Cited by 31
Oncogenic Pathways in Neurodegenerative Diseases
Varela, L., & García-Rendueles, M. E. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063223 · Cited by 30
The Impact of the Cancer Microenvironment on Macrophage Phenotypes
Ham, S., Lima, L. G., Lek, E. S. H., & Möller, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01308 · Cited by 28
“Additionally, sEVs might change extracellular matrix composition via MT1-MMP and c-myc, which induces cancer cells migration and invasion (78, 79).”
BackgroundDoha, Z. O., & Sears, R. C. (2023) · Pathophysiology · doi:10.3390/pathophysiology30030031 · Cited by 27
“The MYC oncogene is a central driver in multiple cancers, such as breast cancer [25], liver cancer [26], colorectal carcinoma [27], prostatic neoplasia [28], ovarian cancer and lung cancer [8].”
BackgroundAlSultan, D., Kavanagh, E. L., O’Grady, S., Eustace, A. J., Castell, A., Larsson, L., Crown, J. P., Madden, S. F., & Duffy, M. J. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01018-w · Cited by 27
A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis
Chen, R., Wu, W., Chen, S., Liu, Z.-Z., Wen, Z., Yu, J., Zhang, L.-B., Liu, Z., Zhang, J., Luo, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831542 · Cited by 26
“org 12 therapeutic target design, and potential therapeutic drug screening (39).”
BackgroundSelf-citationSullivan, D. K., Deutzmann, A., Yarbrough, J., Krishnan, M. S., Gouw, A. M., Bellovin, D. I., Adam, S. J., Liefwalker, D. F., Dhanasekaran, R., & Felsher, D. W. (2022) · Oncogene · doi:10.1038/s41388-022-02458-9 · Cited by 25
Self-citationMcAnulty, J., & DiFeo, A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249486 · Cited by 28
“MYC amplification is found in 21% of patients across 33 different cancers [36], particularly breast cancer, lung squamous cell carcinoma, uterine carcinoma, esophageal carcinoma, and ovarian cancer [25] (Figure 1).”
BackgroundZhang, L., Yang, C., Huang, Y., Huang, H., Yuan, X., Zhang, P., Ye, C., Wei, M., Wang, Y., Luo, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111155 · Cited by 26
Self-citationWang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.551160 · Cited by 27
“For example, MYC is mutually exclusive with PIK3CA, PTEN, APC, or BRAF alterations (40), suggesting that MYC is a distinct driver gene.”
BackgroundSelf-citationThege, F. I., Rupani, D. N., Barathi, B. B., Manning, S. L., Maitra, A., Rhim, A. D., & Wörmann, S. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4009 · Cited by 25
Zeng, T., Li, B., Shu, X., Pang, J., Wang, H., Cai, X., Liao, Y., Xiao, X., Chong, Y., Gong, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1183474 · Cited by 25
“Due to the intricacy of tumorigenesis, pan-cancer analysis is frequently employed in tumor research uncovering the similarity and heterogeneity of various tumor genes and involved biological processes, providing insight into cancer treatment and prevention (3, 4).”
BackgroundLin, A.-P., Qiu, Z., Ethiraj, P., Sasi, B., Jaafar, C., Rakheja, D., & Aguiar, R. C. T. (2022) · Leukemia · doi:10.1038/s41375-021-01489-7 · Cited by 25
E-box binding transcription factors in cancer
Pan, Y., van der Watt, P. J., & Kay, S. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1223208 · Cited by 24
Grzes, M., Oroń, M., Staszczak, Z., Jaiswar, A., Nowak-Niezgoda, M., & Walerych, D. (2020) · Cancers · doi:10.3390/cancers12061532 · Cited by 24
“CMYC alterations are usually exclusive with BRAF, APC, PTEN and PIK3CA alterations [58].”
BackgroundFOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
Tsai, J. W., Cejas, P., Wang, D. K., Patel, S. K., Wu, D. W., Arounleut, P., Wei, X., Zhou, N., Syamala, S., Dubois, F. P. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0671 · Cited by 25
Self-citationNi, Y., Chien, P., Hsieh, H.-C., Shen, H., Lee, H., Chen, S.-M., & Chang, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113276 · Cited by 24
Self-citationXu, W., Liu, S., Zhang, G., Liu, J., & Cao, G. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2143614 · Cited by 24
Self-citationNguyen, H. V., Vandenberg, C. J., Ng, A. P., Robati, M., Anstee, N. S., Rimes, J. S., Hawkins, E. D., & Cory, S. (2020) · Blood · doi:10.1182/blood.2019003014 · Cited by 25
The roles of FGFR3 and c-MYC in urothelial bladder cancer
Bogale, D. E. (2024) · Discover Oncology · doi:10.1007/s12672-024-01173-z · Cited by 27
Testicular germ cell tumors arise in the absence of sex-specific differentiation
Webster, N. J., Maywald, R. L., Benton, S. M., Dawson, E. P., Murillo, O. D., LaPlante, E. L., Milosavljevic, A., Lanza, D. G., & Heaney, J. D. (2021) · Development · doi:10.1242/dev.197111 · Cited by 23
The MYCL and MXD1 transcription factors regulate the fitness of murine dendritic cells
Anderson, D. A., Murphy, T. L., Eisenman, R. N., & MURPHY, K. M. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915060117 · Cited by 24
Self-citationTargeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC
Lankes, K., Hassan, Z., Doffo, J., Schneeweis, C., Lier, S., Öllinger, R., Rad, R., Krämer, O. H., Keller, U. B., Saur, D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12835 · Cited by 22
Tacrolimus inhibits oral carcinogenesis through cell cycle control
Li, Y., Wang, Y., Li, J., Ling, Z., Chen, W., Zhang, L., Hu, Q., Wu, T., Cheng, B., Wang, Y., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111545 · Cited by 22
Self-citationUranishi, K., Hirasaki, M., Kitamura, Y., Mizuno, Y., Nishimoto, M., Suzuki, A., & Okuda, A. (2021) · Stem Cells · doi:10.1002/stem.3433 · Cited by 22
“However, unlike Myc family proteins, MGA belongs to the MXD/MAD transcriptional repressor family, which functions antagonistically against Myc activity by competing with Myc for dimerization with MAX as well as for subsequent DNA binding to E-box sequences (Baudino and Cleveland, 2001; Grandori et al., 2000; Llabata e…”
BackgroundKwon, M., Oh, T., Jang, M., Kim, G., Kim, J., Ryu, H. W., Oh, S., Jang, J., Ahn, J. S., & Ko, S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174938 · Cited by 23
Self-citationOncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors
Khazamipour, N., Al-Nakouzi, N., Oo, H. Z., Ørum-Madsen, M. S., Steinø, A., Sorensen, P. H. B., & Daugaard, M. (2020) · Cells · doi:10.3390/cells9040818 · Cited by 22
“The c-myc (MYC) proto-oncogene displays strong expression in early placenta [9] and is also frequently increased in human cancers [10,11].”
BackgroundTargeted therapies in hepatocellular carcinoma: past, present, and future
Gujarathi, R., Franses, J. W., Pillai, A., & Liao, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432423 · Cited by 22
“The MYC proto-oncogenes are known to encode transcription factors that are frequently activated oncoproteins in a wide array of human cancers (139, 140).”
BackgroundSystems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming
Brashears, C. B., Barlin, M., Ehrhardt, W. R., Rathore, R., Schultze, M., Tzeng, S.-C., Tine, B. A. V., & Held, J. M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02899-8 · Cited by 21
“…arginine starvation, as these approaches have proven effective in delineating the adaptive changes involved in highly pleiotropic phenotypes such as drug resistance (Zecena et al, 2018; Galluzzi et al, 2014), Myc activation, and various metabolic changes (Tomita & Kami, 2012; Schaub et al, 2018).”
BackgroundChi, Y., Yeh, T., Ke, Y., Lin, W., Tsai, C., Wang, W.-P., Chen, Y., Su, Y., Wang, P., Chen, Y.-F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01806 · Cited by 21
Self-citationChan, T., Chen, Y.-T., Tan, K., Wu, C.-L., Wu, W.-J., Li, W.-M., Wang, J.-M., Shiue, Y., & Li, C.-F. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.674 · Cited by 16
Self-citationMakawy, A. I. E., Abdel‐Aziem, S. H., Mohammed, S. E., Ibrahim, F. M., EL-Kader, H. A. A., Sharaf, H. A., Youssef, D. A., & Mabrouk, D. M. (2024) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-01161-3 · Cited by 23
“Many of the genetic alterations that occur in tumors decouple MYC expression from its normal regulatory constraints, thereby resulting in an elevation of MYC proteins that are less sensitive to normal and extracellular signals (Schaub et al. 2018).”
BackgroundMyc-Miz-1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ
Zhang, L., Li, J., Xu, H., Shao, X., Fu, L., Hou, Y., Hao, C., Li, W., Joshi, K., Wei, W., et al. (2020) · Blood · doi:10.1182/blood.2019001863 · Cited by 21
Self-citationTargeting MYC: Multidimensional regulation and therapeutic strategies in oncology
Duan, Y., Liu, Z., Wang, Q., Zhang, J., Liu, J., Zhang, Z., & Li, C. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101435 · Cited by 27
“36 e 40 Genomic alterations, such as gene amplification and chromosomal translocations, can lead to increased MYC expression.”
Self-citationTolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability
Igarashi, T., Yano, K., Endo, S., & Shiotani, B. (2024) · Cancers · doi:10.3390/cancers16203507 · Cited by 22
“Pancancer analysis across the 33 cancers of The Cancer Genome Atlas (TCGA) identified focal amplification (28% of the samples) in at least one of the three MYC families, and MYC antagonists were mutated (MGA, 4% of samples) or deleted (MNT, 10% of samples) [79].”
BackgroundTargeting c-MYC has a key role in hepatocellular carcinoma therapy
Dai, P., & Wang, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104786 · Cited by 22
Self-citationMYC inhibitors in multiple myeloma
Martínez-Martín, S., & Soucek, L. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.55 · Cited by 21
Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia
Wang, H., Lu, J. L., Alencastro, F., Roberts, A., Fiedor, J., Carroll, P. A., Eisenman, R. N., Ranganathan, S., Torbenson, M. S., Duncan, A. W., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.018 · Cited by 18
Self-citationLOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA
Xu, T., Yu, T., Xie, M., Fang, Y., Xu, T., Pan, Y.-T., Ma, P., & Shu, Y. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01348-z · Cited by 20
“c-MYC can bind over 10–15% of all promoters [31], thus, the upstream sequences of LOC101929709 were further analysed by 2000 bp, and a putative binding site of c-MYC was predicted [32] (Fig.”
BackgroundThe prognostic value and immunological role of CD44 in pan-cancer study
Chen, S., Zhang, S., Chen, S., & Ma, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-34154-3 · Cited by 23
Cazarin, J., DeRollo, R. E., Shahidan, S. N. A. B. A., Burchett, J. B., Mwangi, D., Krishnaiah, S., Hsieh, A. L., Walton, Z. E., Brooks, R. C., Mello, S. S., et al. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010904 · Cited by 22
“…functions in cancer, which may depend on 1) the degree to which MYC is overexpressed, 2) which promoters and enhancers it binds, 3) if MYC cooperates with other transcription factors such as MIZ1 to inhibit expression of certain genes, and 4) if MYC strongly regulates pause release [27,30,50–53].”
InfluentialTargeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2
Vogt, M., Stanković, N. D., Cruz-Garcia, Y., Hofstetter, J., Schneider, K., Kuybu, F., Hauck, T., Adhikari, B., Hamann, A., Rocca, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331519 · Cited by 24
Fabris, F., Palmer, D. H., de Magalhães, J. P., & Freitas, A. A. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz028 · Cited by 21
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer
Yang, X., Fan, D., Troha, A. H., Ahn, H. M., Qian, K., Liang, B., Du, Y., Fu, H., & Ivanov, A. A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116324 · Cited by 20
Clapper, E., Wang, S., Raninga, P. V., Trapani, G. D., & Tonissen, K. F. (2020) · Antioxidants · doi:10.3390/antiox9030207 · Cited by 19
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
Deutzmann, A., Sullivan, D. K., Dhanasekaran, R., Li, W., Chen, X., Tong, L., Mahauad‐Fernandez, W. D., Bell, J., Mosley, A. R., Koehler, A. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45128-y · Cited by 22
Self-citationExploring MYC relevance to cancer biology from the perspective of cell competition
Paglia, S., Sollazzo, M., Giacomo, S. D., Strocchi, S., & Grifoni, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.009 · Cited by 18
Windmöller, B. A., Beshay, M., Helweg, L. P., Flottmann, C., Beermann, M., Förster, C., Wilkens, L., Greiner, J. F. W., Kaltschmidt, C., & Kaltschmidt, B. (2021) · Cells · doi:10.3390/cells10051024 · Cited by 18
“Within a recent pan-cancer study, Schaub and coworkers identified MYC family members amplified in up to 33% of all lung adenocarcinomas [15].”
BackgroundComprehensive Analysis of ESRRA in Endometrial Cancer
Wang, S., & Huo, X. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/1533033821992083 · Cited by 18
Deng, C., Guo, H., Yan, D., Liang, T., Ye, X., & Li, Z. (2021) · BioMed Research International · doi:10.1155/2021/5546612 · Cited by 18
RetractedThe FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
Giacomini, A., Taranto, S., Gazzaroli, G., Faletti, J., Capoferri, D., Marcheselli, R., Sciumé, M., Presta, M., Sacco, A., & Roccaro, A. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03217-2 · Cited by 19
“As concerns MYC gene amplifications, they are found in both hematopoietic and non-hematopoietic tumors [36].”
BackgroundSolares, S., León, J., & García-Gutiérrez, L. (2024) · Cancers · doi:10.3390/cancers16244212 · Cited by 18
“So, it EBV-transforming genes (e.g., EBNA2, LMP1), a “hit and run mechanism” by which these genes or the translocation-promoting EBNA3C is expressed after infection contributes to B cell proliferation and then becomes silenced in the growing lymphoma, cannot be ruled out.”
InfluentialA PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer
Henry, K. E., Dacek, M. M., Dilling, T. R., Caen, J. D., Fox, I. L., Evans, M. J., & Lewis, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1485 · Cited by 18
Wang, X., Langer, E. M., Daniel, C. J., Janghorban, M., Wu, V. F., Wang, X., & Sears, R. C. (2020) · Oncogenesis · doi:10.1038/s41389-020-00261-3 · Cited by 18
The Multiple Faces of MNT and Its Role as a MYC Modulator
Liaño-Pons, J., Arsenian‐Henriksson, M., & León, J. (2021) · Cancers · doi:10.3390/cancers13184682 · Cited by 17
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy
Gitareja, K., Chelliah, S. S., Sanij, E., Sandhu, S. K., Kang, J., & Khot, A. S. (2025) · Cancers · doi:10.3390/cancers17152534 · Cited by 20
“Cancer-associated genetic alterations in MYC, PIK3CA, PTEN, KRAS, and BRAF dysregulate growth-promoting signals, enhancing ribosome production and protein synthesis [137,138].”
Relating individual cell division events to single-cell ERK and Akt activity time courses
Stern, A. D., Smith, G. R., SANTOS, L. V. D. S., Sarmah, D., Zhang, X., Lu, X., Iuricich, F., Pandey, G. S., Iyengar, R., & Birtwistle, M. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-23071-6 · Cited by 19
Self-citationRegulation of SUMOylation on RNA metabolism in cancers
Cao, Y., Huang, C., Zhao, X., & Yu, J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1137215 · Cited by 17
Agudo‐Ibáñez, L., Morante, M., García-Gutiérrez, L., Quintanilla, A., Rodríguez, J., Múñoz, A., León, J., & Crespo, P. (2023) · Science Signaling · doi:10.1126/scisignal.adg4193 · Cited by 17
Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer
Cyberski, T. F., Singh, A., Korzinkin, M., Mishra, V., Pun, F. W., Shen, L., Wing, C., Cheng, X., Baird, B. J., Miao, Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00606-w · Cited by 17
“While MYC ampli fi cation is well described in epithelial-type malignancies and associated with a poor prognosis 25,72,73 , its role in HNSCC therapeutic resistance and immune evasion has not been characterized.”
NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma
Dang, H. T., Pomyen, Y., Martin, S. P., Dominguez, D. A., Yim, S. Y., Lee, J., Budhu, A., Shah, A. P., Bodzin, A. S., & Wang, X. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-39727-9 · Cited by 17
Self-citationLiu, S., Wu, B., Li, X., Zhao, L., Wu, W., & Ai, S. (2021) · Journal of Oncology · doi:10.1155/2021/2719172 · Cited by 15
Chen, Y., Léon-Letelier, R. A., Sater, A. H. A., Vykoukal, J. V., Dennison, J. B., Hanash, S., & Fahrmann, J. F. (2023) · Cancers · doi:10.3390/cancers15030623 · Cited by 17
Targeting MYC-driven lymphoma: lessons learned and future directions
Martínez-Martín, S., Beaulieu, M.-È., & Soucek, L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.127 · Cited by 18
Chen, J., Zhu, H., Chen, S., & Mi, H. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s447319 · Cited by 17
Bi, G., Liang, J., Zheng, Y., Li, R., Zhao, M., Huang, Y., Zhan, C., Xu, S., & Fan, H. X. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02773-x · Cited by 15
Self-citationPark, J., Cho, H.-G., Park, J., Lee, G., Kim, H. S., Paeng, K., Song, S., Park, G., Ock, C., & Chae, Y. K. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.01.006 · Cited by 16
Self-citationHurd, M., Pino, J. J., Jang, K., Allevato, M. M., Vorontchikhina, M., Ichikawa, W., Zhao, Y., Gates, R., Villalpando, E., Hamilton, M., et al. (2023) · Genes & Development · doi:10.1101/gad.350736.123 · Cited by 16
“The MYC proto-oncogene (also known as c-MYC ) is amplified or activated in numerous human cancers, often leading to overexpression of the MYC oncoprotein, which correlates with increased tumor aggressiveness and poor prognosis (Vita and Henriksson 2006; Dang 2012; Schaub et al. 2018).”
Wang, Z., Gu, Y. H., Liu, Y., Wang, Z., Chen, X., Wang, H., Zhang, W., Jin, G., & Cao, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02307-7 · Cited by 15
Self-citationThe hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy
Tufail, M., Gong, K., Ijaz, B., Patel, H. H., Lui, W., Wang, X., & Li, J. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101355 · Cited by 16
Self-citationTelomere Maintenance in Pediatric Cancer
Ackermann, S., & Fischer, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235836 · Cited by 15
Lafita‐Navarro, M. C., Liaño-Pons, J., Quintanilla, A., Varela, I., Blanco, R. E., Ourique, F., Bretones, G., Aresti, J., Molina, E., Carroll, P. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010389 · Cited by 15
Self-citationClinical implications of chromatin accessibility in human cancers
Liu, Y. (2020) · Oncotarget · doi:10.18632/oncotarget.27584 · Cited by 15
Self-citationThe Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions
Nirala, B. K., & Yustein, J. T. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37304 · Cited by 19
McClure, M. B., Kogure, Y., Ansari‐Pour, N., Saito, Y., Chao, H., Shepherd, J. H., Tabata, M., Olopade, O. I., Wedge, D. C., Hoadley, K. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0073 · Cited by 14
Self-citationIijima, K., Nakamura, H., Takada, K., Hayasaka, N., Kubo, T., Umeyama, Y., Iyama, S., Miyanishi, K., Kobune, M., & Kato, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12807 · Cited by 16
Schaafsma, E., Zhao, Y., Zhang, L., Li, Y., & Cheng, C. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0526 · Cited by 12
Metadata
- Authors
- Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., Ayer, D. E., Hurlin, P. J., Cherniack, A. D., Eisenman, R. N., Bernard, B., Grandori, C., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., Kasapi, M., Ferguson, M. L., Hutter, C. M., Sofia, H. J., Tarnuzzer, R., Wang, Z., Yang, L., Zenklusen, J. C., Zhang, J. (., Chudamani, S., Liu, J., Lolla, L., Naresh, R., Pihl, T., Sun, Q., Wan, Y., Wu, Y., Cho, J., DeFreitas, T., Frazer, S., Gehlenborg, N., Getz, G., Heiman, D. I., Kim, J., Lawrence, M. S., Lin, P., Meier, S., Noble, M. S., Saksena, G., Voet, D., Zhang, H., Bernard, B., Chambwe, N., Dhankani, V., Knijnenburg, T., Kramer, R., Leinonen, K., Liu, Y., Miller, M., Reynolds, S., Shmulevich, I., Thorsson, V., Zhang, W., Akbani, R., Broom, B. M., Hegde, A. M., Ju, Z., Kanchi, R. S., Korkut, A., Li, J., Liang, H., Ling, S., Liu, W., Lu, Y., Mills, G. B., Ng, K.-S., Rao, A., Ryan, M., Wang, J., Weinstein, J. N., Zhang, J., Abeshouse, A., Armenia, J., Chakravarty, D., Chatila, W. K., de Bruijn, I., Gao, J., Gross, B. E., Heins, Z. J., Kundra, R., La, K., Ladanyi, M., Luna, A., Nissan, M. G., Ochoa, A., Phillips, S. M., Reznik, E., Sanchez-Vega, F., Sander, C., Schultz, N., Sheridan, R., Sumer, S. O., Sun, Y., Taylor, B. S., Wang, J., Zhang, H., Anur, P., Peto, M., Spellman, P., Benz, C., Stuart, J. M., Wong, C. K., Yau, C., Hayes, D. N., Parker, J. S., Wilkerson, M. D., Ally, A., Balasundaram, M., Bowlby, R., Brooks, D., Carlsen, R., Chuah, E., Dhalla, N., Holt, R., Jones, S. J. M., Kasaian, K., Lee, D., Ma, Y., Marra, M. A., Mayo, M., Moore, R. A., Mungall, A. J., Mungall, K., Robertson, A. G., Sadeghi, S., Schein, J. E., Sipahimalani, P., Tam, A., Thiessen, N., Tse, K., Wong, T., Berger, A. C., Beroukhim, R., Cherniack, A. D., Cibulskis, C., Gabriel, S. B., Gao, G. F., Ha, G., Meyerson, M., Schumacher, S. E., Shih, J., Kucherlapati, M. H., Kucherlapati, R. S., Baylin, S., Cope, L., Danilova, L., Bootwalla, M. S., Lai, P. H., Maglinte, D. T., Van Den Berg, D. J., Weisenberger, D. J., Auman, J. T., Balu, S., Bodenheimer, T., Fan, C., Hoadley, K. A., Hoyle, A. P., Jefferys, S. R., Jones, C. D., Meng, S., Mieczkowski, P. A., Mose, L. E., Perou, A. H., Perou, C. M., Roach, J., Shi, Y., Simons, J. V., Skelly, T., Soloway, M. G., Tan, D., Veluvolu, U., Fan, H., Hinoue, T., Laird, P. W., Shen, H., Zhou, W., Bellair, M., Chang, K., Covington, K., Creighton, C. J., Dinh, H., Doddapaneni, H., Donehower, L. A., Drummond, J., Gibbs, R. A., Glenn, R., Hale, W., Han, Y., Hu, J., Korchina, V., Lee, S., Lewis, L., Li, W., Liu, X., Morgan, M., Morton, D., Muzny, D., Santibanez, J., Sheth, M., Shinbrot, E., Wang, L., Wang, M., Wheeler, D. A., Xi, L., Zhao, F., Hess, J., Appelbaum, E. L., Bailey, M., Cordes, M. G., Ding, L., Fronick, C. C., Fulton, L. A., Fulton, R. S., Kandoth, C., Mardis, E. R., McLellan, M. D., Miller, C. A., Schmidt, H. K., Wilson, R. K., Crain, D., Curley, E., Gardner, J., Lau, K., Mallery, D., Morris, S., Paulauskis, J., Penny, R., Shelton, C., Shelton, T., Sherman, M., Thompson, E., Yena, P., Bowen, J., Gastier-Foster, J. M., Gerken, M., Leraas, K. M., Lichtenberg, T. M., Ramirez, N. C., Wise, L., Zmuda, E., Corcoran, N., Costello, T., Hovens, C., Carvalho, A. L., de Carvalho, A. C., Fregnani, J. H., Longatto-Filho, A., Reis, R. M., Scapulatempo-Neto, C., Silveira, H. C. S., Vidal, D. O., Burnette, A., Eschbacher, J., Hermes, B., Noss, A., Singh, R., Anderson, M. L., Castro, P. D., Ittmann, M., Huntsman, D., Kohl, B., Le, X., Thorp, R., Andry, C., Duffy, E. R., Lyadov, V., Paklina, O., Setdikova, G., Shabunin, A., Tavobilov, M., McPherson, C., Warnick, R., Berkowitz, R., Cramer, D., Feltmate, C., Horowitz, N., Kibel, A., Muto, M., Raut, C. P., Malykh, A., Barnholtz-Sloan, J. S., Barrett, W., Devine, K., Fulop, J., Ostrom, Q. T., Shimmel, K., Wolinsky, Y., Sloan, A. E., De Rose, A., Giuliante, F., Goodman, M., Karlan, B. Y., Hagedorn, C. H., Eckman, J., Harr, J., Myers, J., Tucker, K., Zach, L. A., Deyarmin, B., Hu, H., Kvecher, L., Larson, C., Mural, R. J., Somiari, S., Vicha, A., Zelinka, T., Bennett, J., Iacocca, M., Rabeno, B., Swanson, P., Latour, M., Lacombe, L., Têtu, B., Bergeron, A., McGraw, M., Staugaitis, S. M., Chabot, J., Hibshoosh, H., Sepulveda, A., Su, T., Wang, T., Potapova, O., Voronina, O., Desjardins, L., Mariani, O., Roman-Roman, S., Sastre, X., Stern, M.-H., Cheng, F., Signoretti, S., Berchuck, A., Bigner, D., Lipp, E., Marks, J., McCall, S., McLendon, R., Secord, A., Sharp, A., Behera, M., Brat, D. J., Chen, A., Delman, K., Force, S., Khuri, F., Magliocca, K., Maithel, S., Olson, J. J., Owonikoko, T., Pickens, A., Ramalingam, S., Shin, D. M., Sica, G., Van Meir, E. G., Zhang, H., Eijckenboom, W., Gillis, A., Korpershoek, E., Looijenga, L., Oosterhuis, W., Stoop, H., van Kessel, K. E., Zwarthoff, E. C., Calatozzolo, C., Cuppini, L., Cuzzubbo, S., DiMeco, F., Finocchiaro, G., Mattei, L., Perin, A., Pollo, B., Chen, C., Houck, J., Lohavanichbutr, P., Hartmann, A., Stoehr, C., Stoehr, R., Taubert, H., Wach, S., Wullich, B., Kycler, W., Murawa, D., Wiznerowicz, M., Chung, K., Edenfield, W. J., Martin, J., Baudin, E., Bubley, G., Bueno, R., De Rienzo, A., Richards, W. G., Kalkanis, S., Mikkelsen, T., Noushmehr, H., Scarpace, L., Girard, N., Aymerich, M., Campo, E., Giné, E., Guillermo, A. L., Van Bang, N., Hanh, P. T., Phu, B. D., Tang, Y., Colman, H., Evason, K., Dottino, P. R., Martignetti, J. A., Gabra, H., Juhl, H., Akeredolu, T., Stepa, S., Hoon, D., Ahn, K., Kang, K. J., Beuschlein, F., Breggia, A., Birrer, M., Bell, D., Borad, M., Bryce, A. H., Castle, E., Chandan, V., Cheville, J., Copland, J. A., Farnell, M., Flotte, T., Giama, N., Ho, T., Kendrick, M., Kocher, J.-P., Kopp, K., Moser, C., Nagorney, D., O’Brien, D., O’Neill, B. P., Patel, T., Petersen, G., Que, F., Rivera, M., Roberts, L., Smallridge, R., Smyrk, T., Stanton, M., Thompson, R. H., Torbenson, M., Yang, J. D., Zhang, L., Brimo, F., Ajani, J. A., Angulo Gonzalez, A. M., Behrens, C., Bondaruk, J., Broaddus, R., Czerniak, B., Esmaeli, B., Fujimoto, J., Gershenwald, J., Guo, C., Lazar, A. J., Logothetis, C., Meric-Bernstam, F., Moran, C., Ramondetta, L., Rice, D., Sood, A., Tamboli, P., Thompson, T., Troncoso, P., Tsao, A., Wistuba, I., Carter, C., Haydu, L., Hersey, P., Jakrot, V., Kakavand, H., Kefford, R., Lee, K., Long, G., Mann, G., Quinn, M., Saw, R., Scolyer, R., Shannon, K., Spillane, A., Stretch, J., Synott, M., Thompson, J., Wilmott, J., Al-Ahmadie, H., Chan, T. A., Ghossein, R., Gopalan, A., Levine, D. A., Reuter, V., Singer, S., Singh, B., Tien, N. V., Broudy, T., Mirsaidi, C., Nair, P., Drwiega, P., Miller, J., Smith, J., Zaren, H., Park, J.-W., Hung, N. P., Kebebew, E., Linehan, W. M., Metwalli, A. R., Pacak, K., Pinto, P. A., Schiffman, M., Schmidt, L. S., Vocke, C. D., Wentzensen, N., Worrell, R., Yang, H., Moncrieff, M., Goparaju, C., Melamed, J., Pass, H., Botnariuc, N., Caraman, I., Cernat, M., Chemencedji, I., Clipca, A., Doruc, S., Gorincioi, G., Mura, S., Pirtac, M., Stancul, I., Tcaciuc, D., Albert, M., Alexopoulou, I., Arnaout, A., Bartlett, J., Engel, J., Gilbert, S., Parfitt, J., Sekhon, H., Thomas, G., Rassl, D. M., Rintoul, R. C., Bifulco, C., Tamakawa, R., Urba, W., Hayward, N., Timmers, H., Antenucci, A., Facciolo, F., Grazi, G., Marino, M., Merola, R., de Krijger, R., Gimenez-Roqueplo, A.-P., Piché, A., Chevalier, S., McKercher, G., Birsoy, K., Barnett, G., Brewer, C., Farver, C., Naska, T., Pennell, N. A., Raymond, D., Schilero, C., Smolenski, K., Williams, F., Morrison, C., Borgia, J. A., Liptay, M. J., Pool, M., Seder, C. W., Junker, K., Omberg, L., Dinkin, M., Manikhas, G., Alvaro, D., Bragazzi, M. C., Cardinale, V., Carpino, G., Gaudio, E., Chesla, D., Cottingham, S., Dubina, M., Moiseenko, F., Dhanasekaran, R., Becker, K.-F., Janssen, K.-P., Slotta-Huspenina, J., Abdel-Rahman, M. H., Aziz, D., Bell, S., Cebulla, C. M., Davis, A., Duell, R., Elder, J. B., Hilty, J., Kumar, B., Lang, J., Lehman, N. L., Mandt, R., Nguyen, P., Pilarski, R., Rai, K., Schoenfield, L., Senecal, K., Wakely, P., Hansen, P., Lechan, R., Powers, J., Tischler, A., Grizzle, W. E., Sexton, K. C., Kastl, A., Henderson, J., Porten, S., Waldmann, J., Fassnacht, M., Asa, S. L., Schadendorf, D., Couce, M., Graefen, M., Huland, H., Sauter, G., Schlomm, T., Simon, R., Tennstedt, P., Olabode, O., Nelson, M., Bathe, O., Carroll, P. R., Chan, J. M., Disaia, P., Glenn, P., Kelley, R. K., Landen, C. N., Phillips, J., Prados, M., Simko, J., Smith-McCune, K., VandenBerg, S., Roggin, K., Fehrenbach, A., Kendler, A., Sifri, S., Steele, R., Jimeno, A., Carey, F., Forgie, I., Mannelli, M., Carney, M., Hernandez, B., Campos, B., Herold-Mende, C., Jungk, C., Unterberg, A., von Deimling, A., Bossler, A., Galbraith, J., Jacobus, L., Knudson, M., Knutson, T., Ma, D., Milhem, M., Sigmund, R., Godwin, A. K., Madan, R., Rosenthal, H. G., Adebamowo, C., Adebamowo, S. N., Boussioutas, A., Beer, D., Giordano, T., Mes-Masson, A.-M., Saad, F., Bocklage, T., Landrum, L., Mannel, R., Moore, K., Moxley, K., Postier, R., Walker, J., Zuna, R., Feldman, M., Valdivieso, F., Dhir, R., Luketich, J., Mora Pinero, E. M., Quintero-Aguilo, M., Carlotti, C. G., Dos Santos, J. S., Kemp, R., Sankarankuty, A., Tirapelli, D., Catto, J., Agnew, K., Swisher, E., Creaney, J., Robinson, B., Shelley, C. S., Godwin, E. M., Kendall, S., Shipman, C., Bradford, C., Carey, T., Haddad, A., Moyer, J., Peterson, L., Prince, M., Rozek, L., Wolf, G., Bowman, R., Fong, K. M., Yang, I., Korst, R., Rathmell, W. K., Fantacone-Campbell, J. L., Hooke, J. A., Kovatich, A. J., Shriver, C. D., DiPersio, J., Drake, B., Govindan, R., Heath, S., Ley, T., Van Tine, B., Westervelt, P., Rubin, M. A., Lee, J. I., Aredes, N. D., & Mariamidze, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Broad Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Utah (US)
- Oregon Health & Science University (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Grandori, Carla
- ORCID
- Schaub, Franz X.
- Richardson, Anne B.
- Shaw, Reid
- Zhao, Wei
- Zhang, Xiaoyang
- Ventura, Andrea
- Ayer, Donald E.
- Hurlin, Peter J.
- Eisenman, Robert N.
- Grandori, Carla
- Felau, Ina
- Kasapi, Melpomeni
- Ferguson, Martin L.
- Sofia, Heidi J.
- Tarnuzzer, Roy
- Yang, Liming
- Zenklusen, Jean C.
- Zhang, Jiashan (Julia)
- Liu, Jia
- Pihl, Todd
- Sun, Qiang
- Wan, Yunhu
- Wu, Ye
- Gehlenborg, Nils
- Getz, Gad
- Heiman, David I.
- Kim, Jaegil
- Lawrence, Michael S.
- Lin, Pei
- Noble, Michael S.
- Saksena, Gordon
- Zhang, Hailei
- Chambwe, Nyasha
- Knijnenburg, Theo
- Miller, Michael
- Zhang, Wei
- Akbani, Rehan
- Broom, Bradley M.
- Hegde, Apurva M.
- Ju, Zhenlin
- Korkut, Anil
- Li, Jun
- Liang, Han
- Liu, Wenbin
- Lu, Yiling
- Mills, Gordon B.
- Rao, Arvind
- Ryan, Michael
- Wang, Jing
- Weinstein, John N.
- Zhang, Jiexin
- Armenia, Joshua
- Chakravarty, Debyani
- Chatila, Walid K.
- Gross, Benjamin E.
- Heins, Zachary J.
- Kundra, Ritika
- Ladanyi, Marc
- Luna, Augustin
- Ochoa, Angelica
- Phillips, Sarah M.
- Reznik, Ed
- Sander, Chris
- Schultz, Nikolaus
- Sun, Yichao
- Taylor, Barry S.
- Zhang, Hongxin
- Spellman, Paul
- Benz, Christopher
- Stuart, Joshua M.
- Wong, Christopher K.
- Yau, Christina
- Hayes, D. Neil
- Parker, Joel S.
- Wilkerson, Matthew D.
- Holt, Robert
- Jones, Steven J.M.
- Marra, Marco A.
- Mayo, Michael
- Mungall, Andrew J.
- Mungall, Karen
- Sadeghi, Sara
- Tam, Angela
- Wong, Tina
- Beroukhim, Rameen
- Cibulskis, Carrie
- Gabriel, Stacey B.
- Ha, Gavin
- Meyerson, Matthew
- Schumacher, Steven E.
- Shih, Juliann
- Kucherlapati, Melanie H.
- Kucherlapati, Raju S.
- Baylin, Stephen
- Cope, Leslie
- Danilova, Ludmila
- Bootwalla, Moiz S.
- Maglinte, Dennis T.
- Weisenberger, Daniel J.
- Auman, J. Todd
- Hoadley, Katherine A.
- Hoyle, Alan P.
- Jones, Corbin D.
- Mieczkowski, Piotr A.
- Perou, Charles M.
- Roach, Jeffrey
- Shi, Yan
- Fan, Huihui
- Hinoue, Toshinori
- Laird, Peter W.
- Shen, Hui
- Zhou, Wanding
- Chang, Kyle
- Covington, Kyle
- Creighton, Chad J.
- Dinh, Huyen
- Doddapaneni, HarshaVardhan
- Drummond, Jennifer
- Gibbs, Richard A.
- Han, Yi
- Korchina, Viktoriya
- Li, Wei
- Morgan, Margaret
- Muzny, Donna
- Sheth, Margi
- Shinbrot, Eve
- Wang, Linghua
- Wheeler, David A.
- Zhao, Fengmei
- Hess, Julian
- Bailey, Matthew
- Ding, Li
- Fronick, Catrina C.
- Fulton, Robert S.
- Kandoth, Cyriac
- Mardis, Elaine R.
- McLellan, Michael D.
- Miller, Christopher A.
- Wilson, Richard K.
- Morris, Scott
- Sherman, Mark
- Bowen, Jay
- Lichtenberg, Tara M.
- Ramirez, Nilsa C.
- Zmuda, Erik
- Corcoran, Niall
- Hovens, Christopher
- Fregnani, José H.
- Reis, Rui M.
- Silveira, Henrique C.S.
- Vidal, Daniel O.
- Anderson, Matthew L.
- Ittmann, Michael
- Huntsman, David
- Kohl, Bernard
- Andry, Chris
- Duffy, Elizabeth R.
- Lyadov, Vladimir
- Paklina, Oxana
- Setdikova, Galiya
- Tavobilov, Mikhail
- Warnick, Ronald
- Berkowitz, Ross
- Feltmate, Colleen
- Horowitz, Neil
- Kibel, Adam
- Raut, Chandrajit P.
- Ostrom, Quinn T.
- Sloan, Andrew E.
- Giuliante, Felice
- Goodman, Marc
- Karlan, Beth Y.
- Somiari, Stella
- Bennett, Joseph
- Iacocca, Mary
- Lacombe, Louis
- Têtu, Bernard
- Bergeron, Alain
- McGraw, Mary
- Hibshoosh, Hanina
- Sepulveda, Antonia
- Wang, Timothy
- Potapova, Olga
- Voronina, Olga
- Desjardins, Laurence
- Mariani, Odette
- Stern, Marc-Henri
- Cheng, Feixiong
- Signoretti, Sabina
- Bigner, Darell
- Lipp, Eric
- Marks, Jeffrey
- McCall, Shannon
- McLendon, Roger
- Secord, Angeles
- Behera, Madhusmita
- Brat, Daniel J.
- Chen, Amy
- Delman, Keith
- Force, Seth
- Khuri, Fadlo
- Magliocca, Kelly
- Maithel, Shishir
- Olson, Jeffrey J.
- Owonikoko, Taofeek
- Ramalingam, Suresh
- Sica, Gabriel
- Zhang, Hongzheng
- Looijenga, Leendert
- Oosterhuis, Wolter
- Zwarthoff, Ellen C.
- Calatozzolo, Chiara
- Cuzzubbo, Stefania
- DiMeco, Francesco
- Finocchiaro, Gaetano
- Mattei, Luca
- Perin, Alessandro
- Pollo, Bianca
- Chen, Chu
- Taubert, Helge
- Wach, Sven
- Wullich, Bernd
- Kycler, Witold
- Murawa, Dawid
- Wiznerowicz, Maciej
- Martin, Julie
- Bubley, Glenn
- Bueno, Raphael
- Richards, William G.
- Kalkanis, Steven
- Mikkelsen, Tom
- Noushmehr, Houtan
- Scarpace, Lisa
- Girard, Nicolas
- Aymerich, Marta
- Giné, Eva
- Tang, Yufang
- Colman, Howard
- Evason, Kimberley
- Gabra, Hani
- Juhl, Hartmut
- Hoon, Dave
- Kang, Koo Jeong
- Beuschlein, Felix
- Breggia, Anne
- Borad, Mitesh
- Bryce, Alan H.
- Chandan, Vishal
- Cheville, John
- Copland, John A.
- Flotte, Thomas
- Ho, Thai
- Kendrick, Michael
- Kocher, Jean-Pierre
- Nagorney, David
- O’Brien, Daniel
- O’Neill, Brian Patrick
- Patel, Tushar
- Petersen, Gloria
- Rivera, Michael
- Roberts, Lewis
- Smyrk, Thomas
- Torbenson, Michael
- Yang, Ju Dong
- Zhang, Lizhi
- Brimo, Fadi
- Ajani, Jaffer A.
- Behrens, Carmen
- Broaddus, Russell
- Czerniak, Bogdan
- Esmaeli, Bita
- Fujimoto, Junya
- Guo, Charles
- Lazar, Alexander J.
- Logothetis, Christopher
- Ramondetta, Lois
- Sood, Anil
- Troncoso, Patricia
- Tsao, Anne
- Wistuba, Ignacio
- Carter, Candace
- Haydu, Lauren
- Jakrot, Valerie
- Kakavand, Hojabr
- Kefford, Richard
- Lee, Kenneth
- Long, Georgina
- Mann, Graham
- Saw, Robyn
- Scolyer, Richard
- Shannon, Kerwin
- Spillane, Andrew
- Stretch, Jonathan
- Thompson, John
- Wilmott, James
- Chan, Timothy A.
- Ghossein, Ronald
- Gopalan, Anuradha
- Levine, Douglas A.
- Singer, Samuel
- Singh, Bhuvanesh
- Broudy, Thomas
- Nair, Praveen
- Smith, Jennifer
- Zaren, Howard
- Park, Joong-Won
- Kebebew, Electron
- Linehan, W. Marston
- Metwalli, Adam R.
- Pinto, Peter A.
- Schiffman, Mark
- Schmidt, Laura S.
- Vocke, Cathy D.
- Wentzensen, Nicolas
- Yang, Hannah
- Moncrieff, Marc
- Goparaju, Chandra
- Melamed, Jonathan
- Pass, Harvey
- Cernat, Mircea
- Arnaout, Angel
- Bartlett, John
- Thomas, George
- Rassl, Doris M.
- Rintoul, Robert C.
- Bifulco, Carlo
- Urba, Walter
- Hayward, Nicholas
- Facciolo, Francesco
- Marino, Mirella
- Piché, Alain
- Chevalier, Simone
- McKercher, Ginette
- Farver, Carol
- Pennell, Nathan A.
- Borgia, Jeffrey A.
- Seder, Christopher W.
- Junker, Kerstin
- Omberg, Larsson
- Manikhas, George
- Alvaro, Domenico
- Bragazzi, Maria Consiglia
- Cardinale, Vincenzo
- Carpino, Guido
- Gaudio, Eugenio
- Dubina, Michael
- Moiseenko, Fedor
- Dhanasekaran, Renumathy
- Becker, Karl-Friedrich
- Janssen, Klaus-Peter
- Cebulla, Colleen M.
- Elder, J. Bradley
- Lehman, Norman L.
- Nguyen, Phuong
- Pilarski, Robert
- Rai, Karan
- Schoenfield, Lynn
- Wakely, Paul
- Lechan, Ronald
- Tischler, Arthur
- Grizzle, William E.
- Henderson, Joel
- Porten, Sima
- Fassnacht, Martin
- Asa, Sylvia L.
- Schadendorf, Dirk
- Couce, Marta
- Graefen, Markus
- Huland, Hartwig
- Sauter, Guido
- Schlomm, Thorsten
- Simon, Ronald
- Tennstedt, Pierre
- Nelson, Mark
- Bathe, Oliver
- Carroll, Peter R.
- Chan, June M.
- Kelley, Robin K.
- Landen, Charles N.
- Phillips, Joanna
- VandenBerg, Scott
- Roggin, Kevin
- Kendler, Ady
- Steele, Ruth
- Jimeno, Antonio
- Forgie, Ian
- Mannelli, Massimo
- Carney, Michael
- Campos, Benito
- Unterberg, Andreas
- Bossler, Aaron
- Ma, Deqin
- Milhem, Mohammed
- Godwin, Andrew K.
- Madan, Rashna
- Adebamowo, Clement
- Adebamowo, Sally N.
- Boussioutas, Alex
- Beer, David
- Giordano, Thomas
- Bocklage, Therese
- Landrum, Lisa
- Moxley, Katherine
- Walker, Joan
- Zuna, Rosemary
- Feldman, Michael
- Dhir, Rajiv
- Luketich, James
- Carlotti, Carlos Gilberto
- Kemp, Rafael
- Tirapelli, Daniela
- Catto, James
- Swisher, Elizabeth
- Creaney, Jenette
- Robinson, Bruce
- Shelley, Carl Simon
- Bradford, Carol
- Carey, Thomas
- Prince, Mark
- Rozek, Laura
- Wolf, Gregory
- Fong, Kwun M.
- Yang, Ian
- Rathmell, W. Kimryn
- Kovatich, Albert J.
- Shriver, Craig D.
- DiPersio, John
- Drake, Bettina
- Govindan, Ramaswamy
- Heath, Sharon
- Ley, Timothy
- Rubin, Mark A.
- Lee, Jung Il
- Aredes, Natália D.
- Mariamidze, Armaz
- Venue
- Cell Systems
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 6
- Issue
- 3
- Pages
- 282-300.e2
- ISSN
- 2405-4712 (ISSN-L)
- PMC
- PMC5892207
- OpenAlex
- W2795073885
- Cited by
- 431
- References
- 112
- Citations by year
- 2026: 36 · 2025: 56 · 2024: 62 · 2023: 53 · 2022: 58 · 2021: 63 · 2020: 57 · 2019: 33 · 2018: 13
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- dx.doi.org
- Licence
- Locations
- Cell Systems (publishedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Florence Research (University of Florence) (submittedVersion, cc-by-nc-nd)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Open Access CRIS of the University of Bern
- Funders
- NIH (4U01CA176303-04, U24CA143867, RO1CA57138, 5R01CA149707)
- SEngine Precision Medicine
- Cure First
- Shriners Hospitals for Children and Leukemia and Lymphoma Society
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- MYC oncogene, MGA, medical nutrition therapy, tumor suppressor, oncogenic drivers, MYC transcription factors, pan-cancer analysis, PIK3CA, PTEN, APC, BRAF, tumor subtypes, immune response, growth factor signaling, chromatin, translation (biology), DNA replication and repair, biomarkers, cancer therapeutics
- MeSH terms
- Chromatin, Humans, Neoplasms, Oncogenes, Repressor Proteins, Transcription Factors, Biomarkers, Tumor, Signal Transduction, Genes, myc, Proto-Oncogene Proteins c-myc, Computational Biology, Genomics, Proteomics, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
